219
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

ORCID Icon, , , ORCID Icon, , & ORCID Icon show all
Pages 659-671 | Received 16 May 2023, Accepted 15 Aug 2023, Published online: 07 Sep 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.